key: cord-0778729-hyvxn1mx
authors: Henn, Matthew R.; O’Brien, Edward J.; Diao, Liyang; Feagan, Brian G.; Sandborn, William J.; Huttenhower, Curtis; Wortman, Jennifer R.; McGovern, Barbara H.; Wang-Weigand, Sherry; Lichter, David I.; Chafee, Meghan; Ford, Chris B.; Bernardo, Patricia; Zhao, Peng; Simmons, Sheri; Tomlinson, Amelia; Cook, David; Pomerantz, Roger; Misra, Bharat K.; Auninš, John G.; Trucksis, Michele
title: A Phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis
date: 2020-08-04
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.07.048
sha: 8ef33e41d01c2091e6e5848d505e616f7545c272
doc_id: 778729
cord_uid: hyvxn1mx

Abstract Background & Aims Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon. Methods We conducted a double-blind trial of SER-287 in 58 adults with active mild-to-moderate UC (modified Mayo scores 4–10, endoscopic subscores ≥1). Participants received 6 days of preconditioning with oral vancomycin (125 mg, 4 times daily) or placebo followed by 8 weeks of oral SER-287 or placebo. Patients were randomly assigned (2:3:3:3) to groups that received placebo followed by either placebo or SER-287 once weekly, or vancomycin followed by SER-287 once weekly or SER-287 once daily. Clinical endpoints included safety and clinical remission (modified Mayo score ≤ 2; endoscopic subscores 0 or 1). Microbiome endpoints included SER-287 engraftment (dose species detected in stool after, but not before, SER-287 administration). Engraftment of SER-287 and changes in microbiome composition and associated metabolites were measured by analyses of stool specimens collected at baseline, after preconditioning, and during and 4 weeks after administration of SER-287 or placebo. Results Proportions of patients with adverse events did not differ significantly among groups. A higher proportion of patients in the vancomycin/SER-287 daily group (40%) achieved clinical remission at week 8 than patients in the placebo/placebo group (0), placebo/SER-287 weekly group (13.3%), or vancomycin/SER-287 weekly group (17.7%) (P=.024 for vancomycin/SER-287 daily vs placebo/placebo). By day 7, higher numbers of SER-287 dose species were detected in stool samples from all SER-287 groups compared with the placebo group (P<.05), but this difference was not maintained beyond day 7 in the placebo/SER-287 weekly group. In the vancomycin groups, a greater number of dose species were detected in stool collected on day 10 and all subsequent time points, through 4 weeks post-dosing, compared with the placebo group (P<.05). A higher number of SER-287 dose species were detected in stool samples on days 7 and 10 from subjects who received daily vs weekly SER-287 doses (P<.05). Changes in fecal microbiome composition and metabolites were associated with both vancomycin/SER-287 groups. Conclusions In this small phase 1b trial of limited duration, the safety and tolerability of SER-287 were similar to placebo. SER-287 following vancomycin was significantly more effective than placebo for induction of remission in patients with active mild-to-moderate UC. Engraftment of dose species was facilitated by vancomycin preconditioning and daily dosing of SER-287.

Bacteroidetes. [1] [2] [3] Spore-forming Firmicutes, particularly the families Clostridiaceae, Lachnospiraceae, and Ruminococcaceae, have an important role in gut homeostasis through production of metabolites, which enhance gastrointestinal barrier and mucosal immune functions. 4 Although the pathogenesis of disease remains unclear, changes in the gastrointestinal microbiome and associated metabolites may be important. [5] [6] [7] UC patients with active disease exhibit lower microbial diversity with depletion of beneficial Firmicutes and relative expansion of pro-inflammatory Enterobacteriaceae. 8 Inflammatory responses are elicited by Enterobacteriaceae via lipopolysaccharide signaling though toll-like receptors. 9 Microbiome ompositional changes are associated with alterations in microbe-associated products, such as short-chain fatty acids (SCFA), secondary bile acids (2°BA), and tryptophan metabolites, implicated in barrier function, mucin production, and colonic inflammation. 5 Temporal shifts in microbial composition and their metabolites have been postulated to precipitate disease flares. 6, 10, 11 Modulating the microbiome and the microbial triggers of inflammation and immune activation may provide an improved therapeutic option with limited off-target effects.

While microbiome modulation with antibiotics or probiotics have not been an effective therapeutic strategy in UC 12 , data from placebo-controlled trials support a benefit for multi-dose fecal microbiota transplant (FMT) 13 , although the mechanism of action is not fully understood. Patients randomized to FMT had increased microbial diversity and a shift towards similarity to the donor microbiome [13] [14] [15] compared with placebo recipients. Importantly, the microbial taxa associated with clinical remission included spore-forming Firmicutes, such as Lachnospiraceae, Ruminococcaceae, and Eubacteriaceae. 8, 13, 15 The potential role of the microbiome in UC pathogenesis coupled with FMT efficacy data, motivated our development of SER-287, as a novel therapeutic. While FMT contains the full spectrum of stool components to modify the microbiome, our approach fractionates sporeforming bacteria to specifically target Firmicutes relevant to gastrointestinal homeostasis. 4 Gram-positive Firmicute spores are isolated and enriched from stool of rigorously-screened healthy donors by ethanol treatment and purification. This process also removes potential pathogens, such as vegetative bacteria, viruses, and 99% of other non-spore components, producing a more refined and safer therapeutic. Spores, which are intrinsically resistant to gastric acid, are formulated into oral capsules. Bacteria that germinate from these spores develop into metabolically-active vegetative bacteria and colonize the colon, a process termed "engraftment."

Our hypothesis was that SER-287 may reduce colonic inflammation by inducing compositional changes in the microbiome and related metabolites favorable to gastrointestinal homeostasis. We conducted a Phase 1b randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of SER-287 in patients with active mild-to-moderate UC. To further evaluate the mechanism of action, the engraftment of SER-287 bacteria and their relationship to broader changes in the gastrointestinal microbiome and related metabolites was evaluated. We also investigated whether vancomycin preconditioning of the gastrointestinal microbiome could enhance engraftment of SER-287 bacteria. We hypothesized that clearance of Gram-positive bacteria with vancomycin may enhance engraftment of SER-287 bacteria by decreasing competition for nutrients and space.

We conducted a randomized, double-blind, placebo-controlled, multiple-dose trial at 20 US sites. The protocol was approved by Investigational Review Boards and patients gave written informed consent. The trial was funded by Seres Therapeutics and designed in conjunction with the academic advisors.

Eligible patients were ≥18 years of age with active mild-to-moderate disease as defined by a total modified Mayo score (TMMS) of 4-10 and an endoscopic subscore ≥ 1; (mild disease TMMS 4-6; moderate disease TMMS 7-10). During the screening period, past medical history and symptom severity were collected. Disease activity and severity was assessed by the TMMS which includes endoscopy, patient reported outcomes of stool frequency and rectal bleeding, and a physician global assessment.

Treatment-naïve patients and those who had failed 5-ASA formulations, thiopurines or biologics were eligible to enroll. Following randomization, patients were required to remain on a stable dose of 5-ASA, oral corticosteroids (≤15 mg daily of prednisone or equivalent), or thiopurines. Biologic therapies, probiotics or treatments delivered by enema or suppository were not permitted. The washout period for biologics was three months and for probiotics and rectal therapies was approximately 14 days. Inclusion and exclusion criteria and allowable medications are in the Supplement.

The trial design is shown in Figure S1 . Patients were randomly assigned, in a 2:3:3:3 ratio, to four arms that incorporated two treatment phases. The first phase consisted of preconditioning with vancomycin (125 mg four times daily) or matching placebo for six days. The second phase consisted of administration of SER-287 (four capsules containing 1x10 7 colony forming units [CFU]) once daily, or once weekly or matching placebo once daily for eight weeks. Subjects who received once weekly SER-287 took placebo capsules on days 2-7 weekly to maintain the blind. Randomization was performed centrally with an interactive web response system and was balanced across drug product lots (Supplement).

Our donor screening and manufacturing program has been reviewed by the FDA and is consistent with their recent publication. 16 Three donors underwent extensive health examination including personal and family medical history, and laboratory screening for chemistries, hematology, urinalysis, and blood and stool viral, bacterial and parasite testing before donating stool. Donors completed physical examinations, questionnaires and laboratory testing during and after the donation period before material was released for manufacturing.

Stool donations underwent Good Manufacturing Process-compliant manufacturing steps including clearance of non-spore forms of bacteria, fungi, parasites and viruses via solvent treatment and by sequential purification steps. Three lots of SER-287 were prepared from three different donors' materials. All stool donations for a lot came from a single donor and all subjects received SER-287 made from a single lot. Non-spore matter was reduced by >200-fold 7 during purification to <5 mg/dose, with final product purity approximately 10-20% spores by weight. No contaminating bioburden was detected in the final product (assay limit of detection 20 CFU/g). The SER-287 lots used in the trial were characterized by direct whole metagenomic shotgun sequencing (MGX) and taxonomic profiling (Supplement). Firmicutes genera identified in lots are in Table S1 .

Clinical evaluations were performed during the screening phase and at the end of the eight-week treatment phase ( Figure S1 ). Endoscopy was scored by central readers who were unaware of the treatment assignment, study visit number or clinical information [https://www.robartsinc.com/]. We evaluated clinical remission (TMMS ≤2 and an endoscopic subscore ≤1), endoscopic improvement (decrease in the endoscopic subscore ≥1) and clinical response (decrease of ≥3 points in TMMS from baseline plus either a decrease of ≥1 point in rectal bleeding subscore or an absolute rectal bleeding subscore of 0 or 1 at week 8.

Safety was assessed from the preconditioning phase through the end of the long-term safety phase. Assessments performed from randomization and for four weeks following completion of study treatment included laboratory values and adverse events classified by system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MeDRA).

Primary endpoints were safety and changes in microbiome composition. Clinical remission, endoscopic improvement and clinical response were secondary endpoints. The safety population comprised all patients who received at least one dose of study drug (vancomycin, SER-287, or placebo). The intent-to-treat population comprised all patients who were randomized. Descriptive statistics were used to summarize baseline characteristics. For the analysis of clinical remission, the proportions of patients achieving clinical remission at week 8 was compared between each SER-287 arm and placebo using a 2-sided Fisher's exact test; a p-value of <0.05 was considered significant. Asymptotic 95% confidence intervals for the rate differences were also estimated. In these analyses an outcome of "failure" was assigned to patients who discontinued treatment prior to study day 48, received a rescue medication for UC flare or who lacked the necessary data for determination of the relevant endpoint. No adjustment for multiple comparisons was made, as the secondary efficacy endpoints were intended to provide only preliminary data on efficacy. A similar approach was taken for analysis of the proportions of patients with clinical and endoscopic response. The rates of treatment-emergent adverse events were described by treatment group. The randomization plan, which included 15 patients into each of the SER-287 arms and 10 patients into the placebo/placebo arm, was determined to be sufficient to provide initial assessment of a potential treatment effect on efficacy, safety and the microbiome.

We evaluated baseline microbiome composition, engraftment of SER-287 bacteria and broader changes in the gastrointestinal microbiome and metabolites using MGX and mass spectrometry J o u r n a l P r e -p r o o f 8 (metabolomics) of stool samples collected prior to treatment and post-treatment. Details are provided in the Supplement; the number of patients with evaluable MGX data from both baseline and post-treatment samples is reported in Table S2 .

Baseline microbiome composition and post-treatment changes were characterized by calculating α-diversity and β-diversity. α-diversity is reported as the number of unique species detected in a single sample. 17 β-diversity, which measures compositional similarity between samples, was calculated using the binary Jaccard index. 17, 18 The binary Jaccard metric measures similarity based on presence or absence of shared species, and ranges in values from 0 to 1, with 1 indicating two samples are identical.

No correction for multiple hypothesis testing was performed as this Phase 1b trial was exploratory; the microbiome data collected was intended to provide preliminary insights on engraftment and microbiome change.

For baseline composition, we compared two summary measures, α-diversity and Enterobacteriaceae abundance, in our study population to an external cohort of UC patients and controls from the Integrative Human Microbiome Project (HMP2). 6, 19 Controls included persons who presented for age-related colorectal cancer screening or patients with gastrointestinal symptoms without IBD.

Two approaches were taken to assess engraftment of drug product species (i.e., "dose-species").

In the first pre-specified analysis, we evaluated the prevalence of SER-287 dose-species in patients at baseline (screening endoscopy visit prior to treatment) and on day 0 (post-vancomycin preconditioning, prior to SER-287 dosing) and days 3, 7, 10, 14, 56 and 84 (post-treatment with SER-287). We defined engrafting species as SER-287 dose-species detected post-treatment that were not detected at baseline. A Mann-Whitney 2-sided test was performed, comparing the number of engrafting species in patients of one arm to patients of another.

In the second post-hoc analysis, the change in compositional similarity between all sporeforming species in the patient microbiomes and the SER-287 dose from baseline to posttreatment was quantified using the Jaccard β-diversity metric. This second complementary approach was performed to avoid underestimation of engraftment by not including species overlapping with drug product, which were present at baseline. 9 baseline following SER-287 or placebo. These compositional changes represent engrafting species from the dose, in addition to species not detected in the dose.

The impact of SER-287 treatment on Enterobacteriaceae species was evaluated post-hoc. Individual species abundances were summed to determine the relative abundance of Enterobacteriaceae as a fraction of all species detected. Patients with paired baseline and 8week stool samples were assessed, and fold-changes in Enterobacteriaceae relative abundance post-treatment was tested using a Wilcoxon signed-rank test.

Using both targeted metabolomics of SCFAs and bile acids (BA) and global metabolomics we evaluated post-hoc how microbe-associated metabolites correlated with SER-287 treatment and clinical remission. Analyses were performed on five SCFAs and nine BAs from the targeted panels and 1328 metabolites identified by global metabolomics. Changes in metabolite abundance post-treatment were assessed based on fold-changes between patients' baseline and post-treatment samples at 8-weeks post-dosing using a Wilcoxon signed-rank test. Direct statistical comparison to placebo was not performed due to the low number of patients with paired samples. Association of metabolite concentrations with clinical remission was assessed at the clinical efficacy endpoint 8-weeks post-dosing. A two-sided Mann-Whitney test was performed to assess whether metabolites differed in remitters versus non-remitters across arms. Table 1 and Figure S2 shows the patient disposition and demographics. Eighty-five patients were screened and 58 enrolled at 20 US sites within 17 months. Thirty-nine patients (67.2%) had left-sided disease; 19 patients (32.8%) had extensive disease. The mean duration since diagnosis for the overall population was 12.2 years.

Most patients (91.4%) had failed at least one UC therapy. Forty-five (77.6%) were receiving stable UC medications at study entry, which mainly included 5-ASA formulations (65.5%); nine patients (15.5%) were receiving more than one medication (e.g., 5-ASA, an immunonomodulator and/or a corticosteroid). Six patients (10.3%) had prior exposure to biologic therapy (i.e., TNF antagonists, anti-integrins or both). Thirteen patients (22.4%) were not receiving UC medications.

SER-287 was generally safe and well-tolerated across treatment arms. ( Table 2 ). Adverse events were mild (67.0%) or moderate (33.0%). One subject from the vancomycin/SER-287 daily dosing arm with a history of depression had a serious adverse event of worsening depression, deemed unrelated to treatment, which did not lead to treatment discontinuation. During the preconditioning phase, seven patients had adverse events, most of which were gastrointestinal: three received placebo and four received vancomycin. (Table S3) .

During the treatment phase and the subsequent four weeks, the most commonly reported adverse events were gastrointestinal disorders, including abdominal pain, constipation, diarrhea, flatulence, and nausea. Rates of gastrointestinal adverse events were lowest among patients who received daily dosing of SER-287 (6.7%) compared to placebo/SER-287 weekly (46.7%), vancomycin/SER-287 weekly (41.2%) and placebo/placebo (45.5%). The rate of infections among those who received daily dosing of SER-287 was similar to placebo (Table S4) .

Treatment discontinuation due to gastrointestinal adverse events occurred in one patient (6.7%) in the placebo/SER-287 weekly arm; two patients (11.8%) in the vancomycin/SER-287 weekly arm and none of the patients on the SER-287 daily dosing or placebo arms ( Table 2) . One patient in the placebo/SER-287 weekly arm (6.7%) discontinued treatment due to a UC flare (deemed unrelated to study drug by the investigator) while one patient (5.9%) in the vancomycin/SER-287 weekly arm and one patient in the vancomycin/SER-287 daily arm (6.7%) discontinued the study prematurely due to perceived lack of efficacy ( Figure S2) .

Overall 84.5% of patients completed induction therapy including 10/11 (90.9%) who received placebo/placebo; 13/15 (86.7%) who received placebo/SER-287 weekly; 14/17 (82.3%) who received vancomycin/SER-287 weekly and 12/15 (80.0%) who received vancomycin/SER-287 daily. Mean adherence with study drug ranged from 84.5% to 86.9% of all dispensed capsules taken across treatment arms.

Patients assigned to the vancomycin/SER-287 daily arm achieved a higher clinical remission rate at week 8 (40%) than those assigned to placebo/placebo (0%), placebo/SER-287 weekly (13.3%), and vancomycin/SER-287 weekly (17.7%) ( Figure 1A) . Remission in the vancomycin/SER-287 daily arm was significantly higher than the placebo/placebo arm (Fisher's exact test, p=0.024). Greater remission was observed in vancomycin/SER-287 daily versus vancomycin/SER-287 weekly suggesting dose-dependence. Endoscopic improvement rates were numerically greater in the SER-287 arms but not significantly different than placebo. ( Figure  1B) . The outcomes for the two weekly dosing regimens of SER-287 were similar. No significant differences in clinical response ( Figure 1C ) were observed in any of the three SER-287 treatment arms compared to placebo. No significant differences in fecal calprotectin and Creactive protein data were observed across arms at 8 weeks.

In comparing the baseline values of our study population to controls from HMP2, 7 no significant differences in α-diversity were seen (Kruskal-Wallis, p > 0.05). Median abundance of Enterobacteriaceae in our study patients trended higher than the UC cohort in HMP2 and significantly higher than the non-IBD healthy cohort (median 0.39%, 0.17%, and 0.02%, respectively; Mann-Whitney p-value=0.003).

In comparing patients with mild or moderate disease, α-diversity did not significantly differ. In moderate patients, Enterobacteriaceae abundance was higher than in mild patients (Mann-Whitney p-value=0.038); moderate patients also had more genera considered pro-inflammatory (e.g., Klebsiella, Proteus). Twelve of 51 patients (24%) had no detectable Enterobacteriaceae; most (75%) had mild UC. In contrast, of the 39 patients (76%) with detectable Enterobacteriaceae, most (63%) had moderate disease.

Engraftment occurred rapidly by day 7 with a significant increase in engrafting species in all SER-287 arms compared to placebo (Figure 2 , Table S5 ). Beyond day 7, the distinction between the placebo/placebo and placebo/SER-287 weekly arms was not significant. In contrast, the favorable effect of antibiotic preconditioning on engraftment was clearly apparent by day 10 for both weekly and daily SER-287 administration and sustained through four weeks post-dosing (Figure 2 , p<0.05 for all comparisons, Table S5 ). In the vancomycin preconditioning arms, a significantly greater number of engrafting species were observed at days 7 and 10 in the SER-287 daily dosing arm compared to the SER-287 weekly dosing arm (p<0.05, Table S5 ). This observation suggests that engraftment is both facilitated by vancomycin preconditioning and is dose-dependent (Figure 2 , Table S5 ). Engraftment at days 7 and 10 was also greater in remitters than non-remitters in all arms combined (Mann-Whitney, p=0.001 and p=0.025); however, this association was not significant within any individual arm or at later timepoints.

In the second assessment of engraftment, based on β-diversity , we observed a similar favorable impact of vancomycin-preconditioning and SER-287 dosing frequency as patient spore composition became most similar to SER-287 drug product species in the vancomycin/SER-287 daily arm ( Figure S3 ). We saw no difference in engraftment as assessed by β-diversity between the placebo/placebo and placebo/SER-287 weekly arms. We also did not observe significant differences in engraftment across drug lots by either measure of engraftment.

Across all species, α-diversity (the number of unique species) did not significantly increase in any arm (p > 0.05 for all arms). However, α-diversity of spore-forming species significantly increased, and was durable in the vancomycin/SER-287 daily dosing arm, consistent with greater engraftment (Table S6) . Through eight weeks, β-diversity was significantly different from baseline only in the arms with SER-287/vancomycin preconditioning indicating changes in overall microbiome composition (Table S7) .

We next sought to characterize compositional changes in the microbiome at finer resolution based on gain and loss of individual species post-treatment ( Figure 3 ). In the placebo/placebo arm, microbiome changes are due to natural fluctuations 19 . Compared to placebo/placebo, minimal compositional shifts were observed in the placebo/SER-287 weekly arm consistent with low magnitude engraftment. In contrast, significant changes were observed in both vancomycin preconditioning arms with a trend towards greater change in the SER-287 daily-dosing arm. To further characterize these changes, we separately evaluated the proportion of species increasing or decreasing in prevalence. More species were gained (Mann-Whitney, p-value=0.022 and 0.014 for vancomycin/SER-287 weekly and vancomycin/SER-27 daily arms, respectively) and lost (Mann-Whitney, p-value=0.004 and 0.006 for vancomycin/SER-287 weekly and vancomycin/SER-287 daily arms respectively) in the vancomycin-preconditioning arms than in the placebo/placebo arm.

Genera of newly-detected species were predominantly spore-formers found in SER-287, such as Clostridium, Gemminger, Dorea, Roseburia, Blautia, and Faecalibacterium; (Figure 3 , blue bars). Genera decreasing post-treatment were predominantly nonspore formers such as 12 Veillonella, Streptococcus, and Bacteroides (Figure 3 , gray bars). Taken together, global changes in the microbiome were associated with engraftment of drug product species (Table  S1 ) and additional changes related to nondrug product species.

We evaluated the effect of SER-287 on Enterobacteriaceae abundance at 8-weeks post-treatment among patients with Enterobacteriaceae detected at baseline (n=29). We observed the greatest decrease of Enterobacteriaceae relative abundance compared to baseline in vancomycin preconditioning arms (median decreases -0.09% and -0.58% for SER-287 weekly and daily, respectively) and a slight increase in placebo preconditioning arms (median increases +0.36% and +0.03% for placebo and SER-287 weekly, respectively) ( Figure S4 , Table S8 ). Furthermore, an association was observed between a decline in Enterobacteriaceae and clinical remission (p-value=0.02; vancomycin/SER-287 weekly + daily arms, Table S9 ).

For SCFA and BA concentrations we assessed: a) change post-treatment within arms and b) association with remission across arms (See methods; Tables S10 & S11). The SCFA hexanoate was positively associated with both SER-287 (p=0.02 in vancomycin/daily dosing arm; Figure  4A ) and clinical remission (p=0.05; Figure 4B ). Butyrate did not significantly change posttreatment, but there was a trend for an increase in the ratio of butyrate:propionate concentrations in the vancomycin/daily dosing arm (p=0.07). We also examined 2°BA lithocholic acid (LCA), deoxycholic acid (DCA), and ursodeoxycholic acid (UDCA). We did not observe a significant change in LCA and DCA post-treatment, but UDCA was negatively-associated with both SER-287 treatment (p=0.047 in the vancomycin/daily dosing arm; Figure 4A ) and clinical remission (p=0.043; Figure 4B ). LCA and DCA increases tended to positively associate with clinical remission (p=0.053 and p=0.09 respectively), with an observed increase in the ratio of LCA:UDCA.

Global LC-MS/MS metabolomics were used to identify metabolites associated with SER-287 treatment and remission. Of the 1328 metabolites in our dataset we conducted three analyses. First, we examined changes in metabolite concentrations relative to pre-treatment baseline (Table S12) . We focused our analysis on the vancomycin-preconditioning arms where SER-287 engraftment was observed at the 8-week time point; in total, 166 metabolites changed (13 increased; 153 decreased, p<0.05). Second, we examined the association of metabolites with outcome (Table S13); 186 metabolites differentiated remitters from non-remitters (57 increased; 129 decreased, p<0.05). Lastly, 38 metabolites were associated with both vancomycin/SER-287 treatment and remission; of these, three metabolites increased and 35 decreased. All three metabolites that increased are amino acid derivatives: N-acetylarginine and two derived from tryptophan (indole & 3-methylindole). The 35 metabolites that decreased include lipids (e.g., sphingolipids, acyl-carnitines, and arachidonate), dinucleotides, taurine-derived metabolites (taurine and N-acetyltaurine), and five unidentified compounds. Three of the 38 metabolites are microbe-associated and affect inflammatory pathways, specifically indole, taurine, and arachidonate ( Figure 4C; Figure 4D) , and several others are host-derived lipids and acylcarnitines known to be perturbed in IBD. 6, [20] [21] [22] J o u r n a l P r e -p r o o f 13 DISCUSSION This first clinical trial of an oral microbiome drug, SER-287, provides evidence of a favorable safety profile and preliminary insights into drug pharmacology and multiple mechanisms of action. In keeping with our hypothesis, SER-287 bacteria engrafted and modulated the microbiome and microbe-associated metabolites of functional relevance to UC. In this small study, we also have preliminary data of an efficacy signal of SER-287 supporting a role for microbiome therapeutics in the treatment of active mild-to-moderate UC.

The safety profile of SER-287, which was the primary safety endpoint, was similar to placebo. The most commonly reported adverse events were gastrointestinal disorders, which were less frequent in the SER-287 daily dosing arm relative to other arms, including placebo. Favorable tolerability might be expected given that SER-287 is composed of Firmicutes, considered important to gastrointestinal health 1, 3 . Safety confirmation in larger trials would establish this therapeutic approach as particularly suitable for monotherapy for milder UC patients or in combination with other agents. Oral vancomycin preconditioning was well-tolerated relative to placebo, consistent with its well-known safety profile.

In this small Phase 1b study, the daily SER-287 regimen was the most effective regimen as assessed by all pre-specified efficacy endpoints. The use of centrally-read endoscopy, a modality that reduces bias in assessment of clinical remission, and was likely critical to determining a benefit of SER-287. 23 Although clinical response rates did not significantly differ between placebo and SER-287 arms, the placebo response rate was high, typical of UC trials conducted in mild-moderately active disease; 24 it is noteworthy that this highly subjective outcome is no longer recommended as a primary endpoint. 24, 25 Clinical remission and endoscopic improvement were highly similar between the two weekly SER-287 regimens, with and without vancomycin preconditioning, suggesting that the direct therapeutic effect of vancomycin was limited. Likewise, we suspect that the efficacy of the daily dosing arm was driven by greater SER-287 drug exposure, although we cannot definitively rule out any impact of vancomycin without a placebo comparator.

We propose engraftment as a key mechanism of action of a live microbiome biotherapeutic. This proposal is based on the hypothesis that a microbiome drug is more likely to have a therapeutic effect if there is measurable engraftment of drug product, which evokes measurable changes in the overall composition of the gut microbiome, associated metabolites, and other functional changes in the host. We propose that engraftment kinetics of a microbiome therapeutic are comparable to small molecule drug pharmacokinetics.

Most ecosytems are stable and generally resistant to colonization. Thus, the ability to engraft is dependent on disruption of the microbial environment. 26, 27 The decision to use an antibiotic as preconditioning therapy was informed by human studies showing the disruptive impact of these drugs on the gut microbial community 28 and pre-clinical studies supporting increased engraftment following antibiotic treatment. For example, in the context of recurrent Clostridium difficile infection, antibiotic-induced reductions in gut microbial diversity 29 can be restored through engraftment of orally-dosed bacteria. 30 Oral vancomycin was specifically evaluated as a preconditioning regimen based on its well-known safety profile; lack of systemic absorption; its spectrum of antibacterial activity and the hypothesis that reduction of pre-existing Gram-positive J o u r n a l P r e -p r o o f 14 bacteria would create an ecological niche for engraftment of Gram-positive SER-287 species. The two SER-287 weekly dosing arms affirm that vancomycin preconditioning facilitated engraftment, although we were not able to definitively link engraftment to efficacy. The rules of engraftment may also be influenced by drug dosing frequency. 27 Daily dosing of SER-287 led to greater engraftment at earlier time points compared to weekly dosing consistent with a dosedependent effect. Although, we did not observe differences in engraftment or clinical outcome across drug product lots, further evaluation in future trials will confirm whether or not SER-287 is associated with a donor effect.

SER-287 engraftment was associated with gains and losses of both spore-forming and non-sporeforming species. Post-treatment genera gained included Firmicutes related to dose-species, such as Clostridium, Gemminger, Dorea, Roseburia, Blautia, and Faecalibacterium, implicated in colonocyte health, epithelial gut integrity and regulation of immune tolerance. 31 We only observed a significant increase in the α-diversity of spore-forming Firmicutes in the SER-287 daily dosing arm. Additionally, declines in Enterobacteriaceae abundance, including proinflammatory species such as Klebsiella pneumoniae and Proteus mirabilis, 9, 32 were associated with remission in the two SER-287 treatment arms following vancomycin preconditioning. The clinical significance of this finding is unclear given the limited sample size, the heterogeneity of Enterobacteriaceae detection at baseline and the magnitude of the changes. Collectively, these observations support that modulation of the microbiome was due to replacement of pre-existing spore-formers with drug product species in addition to changes in species not in the dose. These data suggest that total diversity may be less informative than the specific species that are interacting and functioning within the microbial network. 33, 34 In support of that concept, baseline α-diversity was not associated with disease severity whereas baseline Enterobacteriaceae abundance was higher in moderate subjects. We propose that these compositional changes in non-dose related species represent one significant aspect of the mechanism of action and pharmacodynamics of SER-287.

Changes in microbe-associated metabolites are another dimension of SER-287 pharmacodynamics. In post-hoc analyses, we focused on metabolites that impact epithelial barrier integrity and signaling of anti-inflammatory pathways. Consistent with the HMP2 IBD cohort 6 we did not observe significant increases in abundances of butyrate or 2°BAs DCA and LCA in SER-287 recipients. Notably, we did see changes in ratios of metabolites, such as butyrate:propionate and LCA:UDCA suggesting that SER-287 may lead to shifts in the functional pathways utilized with clinical benefit. The metabolites with the strongest associations with both SER-287 treatment and clinical remission are microbe-associated metabolites with relevance to gut homeostasis, such as hexanoate, indole, taurine, and arachidonate. Microbial products of tryptophan metabolism, such as indole, can signal AhR in the gut and impact mucin production, epithelial barrier function, and immune signaling. 5 Arachidonic acid is a precursor of prostaglandins that can impact neutrophil migration across the epithelium. 35, 36 Notably, the constellation of metabolite associations with SER-287 or clinical remission aligns with emerging data from several UC cohort studies 6, 20-22 (Tables S10 through S13). We hypothesize that these associations reflect modulation of multiple metabolic pathways by SER-287 and contribute to its mechanism of action. Although we did not observe a direct overall correlation of SER-287 engraftment with clinical outcomes in this small safety study, we suspect that metabolic correlations are likely a more sensitive indicator of the pharmacodynamics of a microbiome drug; this may become clearer in our Phase 2 trial.

SER-287 offers advantages over other microbiome modulating approaches such as single-strain therapeutics and FMT. Single-strain therapeutics are unlikely to provide the spectrum of functional activity necessary for efficacy. In contrast, FMT represents a broad spectrum of microbes, but due to minimal processing, can also include harmful pathogens. Bacterial infections transmitted thorugh contaminated FMT have uncommonly led to death and hospitalizations. 37, 38 However, since most FMT use has been outside the clinical trial setting, the safety profile of FMT remains unknown. 39 The FDA has also alerted providers of the potential risk of SARS-CoV-2 transmission via FMT due to prolonged fecal shedding. 40 The COVID-19 pandemic is a reminder that FMT will always be vulnerable to emerging infections, when pathogens are unrecognized until after transmission. 41, 42 Additionally, FMT carries risk of transmission of pro-inflammatory strains and potentially carcinogenic bacteria. 9, 43 In contrast, SER-287 is a multifunctional consortia of bacterial spores, purified under stringent manufacturing processes. These processes isolate the microbial components essential to gut homeostasis while inactivating bacteria, parasites, fungi, and viruses, providing a reliable safety net to mitigate risk. 30 Strengths of this trial included its placebo-controlled design, affording an opportunity to examine the impact of a therapeutic intervention on the UC microbiome. Blinded central reads of endoscopic assessments, enhance confidence in the outcomes. 23 The collective and consistent observations relative to clinical outcomes, engraftment, microbiome composition and microbeassociated metabolites are consistent with the biologic activity of SER-287. One limitation was its relatively small sample size, which precludes definitive conclusions about efficacy and safety. A further limitation of our trial was the absence of vancomycin preconditioning followed by placebo. This arm was not included due to concerns about a potential bloom of pro-inflammatory Enterobactericeae following antibiotics alone 44, 45 and the potential risk of Clostridioides difficile infection (CDI). 46 One study of 27 UC subjects who were randomly assigned to antibiotic preconditioning followed by FMT compared to antibiotics alone is particularly informative. 46 CDI occurred in 30% of subjects in the antibiotic alone arm, which the authors attributed to the low diversity state that ensued. In addition, reduction of beneficial Firmicutes and expansion of pro-inflammatory Proteobacteria were observed, which may explain the absence of any clinical remitters in this arm compared to 24% randomized to FMT. Since UC patients are at increased risk of CDI with worse clinical outcomes than those without underlying UC, we chose not to include a vancomycin preconditioning/placebo arm in our Phase 2 trial based on these concerning data. In addition, vancomycin monotherapy is not recommended by society guidelines. 12 These prospective trial data support the favorable impact of SER-287 on the gut microbiota and their associated metabolites through multiple physiological pathways, with important implications for UC management. SER-287 may represent a new therapeutic paradigm for UC with potential advantages with respect to safety and convenience of oral-dosing. Based on these results, daily SER-287 following vancomycin preconditioning is undergoing further evaluation in a Phase 2b trial (Clinicaltrials.gov, #NCT03759041). Table S10 -S13. AEs leading to discontinuation of study drug 0 1 (6.7) 2 (11.8) 0

What you need to know: Background and Context: Firmicutes bacteria produce metabolites that help maintain the intestinal barrier and mucosal immunity. Firmicutes and their associated metabolites are reduced in intestinal microbiota of patients with ulcerative colitis (UC).

New Findings: In a phase 1b trial, administration of SER-287 (Firmicutes spores) following vancomycin preconditioning induced clinical remission in a significantly higher proportion of patients with mild to moderately active UC than placebo. The safety and tolerability of SER-287 were similar to those of placebo.

This was a small study of limited duration (12 weeks)-larger studies are needed.

Impact: SER-287 may induce remission by changing the composition and function of the gut microbiome.

Lay Summary: The authors identified a community of bacteria that are reduced in the intestinal microbiomes of patients with UC but when given orally (in spore form) induces remission in about 40% of patients.

Expected to receive antibiotics within 8 weeks of signing the Informed Consent Form (ICF) (i.e., for planned/anticipated procedure). 15 .

Received an investigational drug within 1 month prior to study entry. 16 .

Received an investigational antibody or vaccine within 3 months prior to study entry. 17.

Previously enrolled in a SER-109 or SER-287 study.

Received an FMT within 6 months prior to study entry. 19 .

Poor concurrent medical risks with clinically significant co-morbid disease such that, in the opinion of the investigator, the subject should not be enrolled including:

a. Subjects with decompensated liver cirrhosis (Child-Pugh Class B or C) or uncontrolled liver disease b.

Prior history of bone marrow transplant c.

Known hypogammaglobulinemia d.

Known severe immunodeficiency e.

Underlying liver function test (LFT) [screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST)] abnormalities greater than 2x upper limit of normal (ULN) f.

Absolute neutrophil count (ANC) < 500 cells/mm3. 20.

Subjects with anatomic or medical contraindications to lower endoscopy (flexible sigmoidoscopy or colonoscopy), including but not necessarily limited to: toxic megacolon; gastrointestinal (GI) fistulas; immediate post-operative status from abdominal surgery; severe coagulopathy; large or symptomatic abdominal aortic aneurysm; or any subject where study physician deems subject at significant risk of complications of lower endoscopy (flexible sigmoidoscopy or colonoscopy).

Unable to stop steroid or mesalamine enemas or suppositories before screening visit.

Unable to stop opiate treatment, unless on a stable dose with no increase in dose planned for the duration of the study. 23 .

Unable to stop probiotics before screening visit.

Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with medical monitor).

Unable to comply with the protocol requirements. 26 .

Any condition that, in the opinion of the investigator, might interfere with study objectives.

Known allergy or intolerance to oral vancomycin. 28.

Known active intravenous drug or alcohol abuse or use of other drugs of abuse.

The complete list of concomitant medications permitted on study included: • Oral aminosalicylates (aminosalicylates taken for at least 6 weeks, with a stable dose for > 2 weeks prior to screening required) 

Subjects receiving any of the above permitted concomitant medications at the time of study entry were required to maintain a stable dosage throughout the study (except for drugs allowed for short term use as noted above), unless investigator judgment required increase, reduction, or discontinuation for safety concerns or medical necessity. Dosing changes due to safety concerns or medical necessity were a cause to discontinue subjects from the study.

UC flares were considered adverse events of special interest defined as a 2-point increase in the partial Mayo score, documented at two contiguous visits after initiation of study drug plus worsening clinical status warranting a change in UC treatment, as determined by the principal investigator. During the subsequent 22-week follow-up period, occurrence of a UC flare was defined by a change in UC medication, as reported by the patient.

Subject stool samples were collected at baseline (prior to vancomycin pre-conditioning), on day 0 (postvancomycin pre-conditioning, prior to SER-287 dosing), and on days 3, 7, 10, 14, 56 and 84 (posttreatment with SER-287). For analyses involving comparisons of baseline to post-treatment microbiome, all subjects with available paired samples are included (*** Table S2 ).

Bacterial DNA was extracted from 200 µl or 0.2g of subject stool and dose samples using the MagAttract PowerSoil DNA Kit (Qiagen, formerly MoBio). Libraries were sequenced on the Illumina HiSeq to a target depth of 5 gigabases (Gb) for subject samples and 10 Gb for SER-287 lots.

Samples were processed per standard iHMP data processing guidelines (https://hmpdacc.org/hmp/resources/): Read pair deduplication was implemented using a custom Python function to remove PCR and sequencing artifacts. Adapter sequences and low-quality sequence data was trimmed using trimmomatic 1 [**Bolger 2014]. Finally, reads were aligned to human and artificial reference sequences using bowtie2 2 [**Langmead and Salzberg 2012] to remove unwanted sequence data (e.g., human DNA or artificial DNA). Raw sequencing data has not been deposited public databases in order to protect the intellectual property of Seres Therapeutics

Species taxonomic profiling of MGX reads for both SER-287 lots and subject stools was performed using the MetaPhlAn2 software 3,4 [** *Segata et al., 2012; Truong et al., 2015] . The curated public reference database used for MetaPhlAn2 includes species-level genomic markers. In addition to these publicly available bacterial species genomes, we added spore-forming genomes from our proprietary Seres strain collection to increase detection of spore-forming species underrepresented in public databases. For all analyses, species were classified as being spore-forming or not spore-forming according to a proprietary, curated annotation of species experimentally demonstrated to form spores or identified in the literature as spore-forming species.

Prior to generation of final taxonomic profiles, all samples were subsampled to the same sequencing depth to account for any correlation between sequencing depth and observed species richness. A subsampling depth of 150,000 reads mapped to the MetaPhlAn2 reference database was used. Any samples with fewer than 150,000 mapped reads were omitted from downstream analysis.The ensuing output from the MetaPhlAn2 taxonomic profiling pipeline is referred to as the "microbiome profile" of a sample.

Short-Chain Fatty Acids (SCFA): Sample preparation and data generation was performed by Metabolon Inc (Durham, NC). Samples were maintained at -80 o C until processed. Samples were analyzed for SCFAs by LC-MS/MS (Metabolon Method TAM135). Human stool samples are spiked with stable labelled internal standards and are subjected to protein precipitation with methanol. After centrifugation, an aliquot of the supernatant is derivatized to form the corresponding SCFA hydrazides. The reaction mixture is diluted, and an aliquot is injected onto an Agilent 1290/AB Sciex QTrap 5500 LC-MS/MS system equipped with a C18 reversed phase UHPLC column. The mass spectrometer is operated in negative mode using electrospray ionization (ESI). The peak area of the individual analyte product ions is measured against the peak area of the product ions of the corresponding internal standards. Quantitation is performed using a weighted linear least squares regression analysis generated from fortified calibration standards prepared immediately prior to each run. Metabolite concentrations are reported in units of microgram of metabolite per gram of stool.

Bile Acids (BA): Sample preparation and data generation was performed at Seres Therapeutics. Samples were maintained at -80 o C until processed. Three sample aliquots were prepared from thawed samples. Aliquot 1 was weighed and spiked with labeled standards at a final concentration of 5μM/mg prior to any further extraction. Aliquots 1 and 2 were homogenized in 10x v/w 50% methanol, incubated on ice for 1h and further extracted with an equal volume of cold acetonitrile. Extracted samples were spun down, filtered and analyzed by targeted LC-MS. Aliquot 2 was spiked with labeled BA standards postextraction, prior to analysis by LC-MS. Aliquot 3 was weighed, dried overnight in an oven at 105 o C, and weighed again to determine the water content of the sample. LC-MS analysis was carried out using an Agilent 1260 series Liquid Chromatograph coupled to a Bruker Compact qTOF mass spectrometer. BA were separated using a Microsolv C18 bidentate column with a gradient of water and acetonitrile. Data was processed using Bruker Compass DataAnalysis software and quantified using calibration curves generated with commercially available pure standards. All data is expressed relative to sample dry weight (ng/mg). Spike in controls were used to determine extraction efficiency of bile acids of interest. Additional controls to ensure quality and consistency across samples and runs were included with every batch analysis on the LC-MS.

Global Metabolomics: Sample preparation and data generation was performed by Metabolon Inc (Durham, NC). Samples were maintained at -80 o C until processed. Proteins were precipitated with methanol (Glen Mills GenoGrinder 2000) followed by centrifugation to remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites. The resulting extract was divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI); one for analysis by RP/UPLC-MS/MS with negative ion mode ESI; one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. All methods utilize a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The scan range varies slightly between methods, but covers approximately 70-1000 m/z. Compounds were identified based on three distinct parameters: Retention index, accurate mass and MS/MS spectrum in comparison to Metabolon's proprietary library of purified standards and recurrent unknown entities. Peaks were quantified using areaunder-the-curve, adjusted for variations across runs and scaled as necessary for further analysis. Missing values were assumed to be below the level of detection for that biochemical with the instrumentation used and were imputed to the observed minimum for that particular biochemical across all samples.

Henn et al.

Metadata for the Integrative Human Microbiome Project was downloaded from the link https://ibdmdb.org/tunnel/products/HMP2/Metadata/hmp2_metadata.csv. Data was accessed March 14, 2018 . Only metagenomics samples with available sequencing files were considered (N = 1338). These represented multiple visits from 106 unique subjects, including nonIBD (N = 50), UC (N = 30), and CD (N = 50) cohorts. For each unique subject, the sample corresponding to the earliest visit number was selected. In cases where multiple samples were attributed the same visit number, the sample with the lowest human read count was selected.

Each sample was then processed using the same steps as the SERES-101 study samples, including all preprocessing steps (read deduplication, trimming, and human read filtering; see Whole metagenomic shotgun (MGX) sequencing). Samples were also subsampled to the same depth as the SERES-101 study samples for comparability (150,000 mapped reads) prior to taxonomic profiling with MetaPhlAn2. Samples with fewer than 150,000 mapped reads were omitted from further analyses.

After all processing steps, a total of 97 samples were available for HMP2 comparative analyses, including samples from 25 nonIBD, 26 UC, and 46 CD unique subjects.

In a post-hoc assessment, the number of flares was low in all arms. The following number of reported UC flares were observed over a 26-week period by treatment arm: five (33.3%) in the placebo/weekly SER-287 arm; one (5.9%) in the vancomycin/weekly SER-287 arm; two (13.3%) in the vancomycin/daily SER-287 arm and three (27.3%) Figure S3 : Engraftment of SER-287 species is dose-dependent and facilitated by vancomycin preconditioning; pre-conditioned patient microbiome samples become more similar to SER-287 dose composition following rebound from Vancomycin. Similarity between a subject's microbiome and SER-287 dose composition is quantified with a binary Jaccard similarity coefficient of spore-forming species in subject samples and SER-287 doses; the change in similarity for each subject and timepoint is relative to that subjects' baseline sample (y-axis) across time (x-axis). Black horizontal dashed line indicates the threshold where a subjects' spore fraction is more (>0) or less (<0) similar to SER-287 post- Table S1 . Spore-forming bacterial taxa identified in SER-287 lots. The three lots of SER-287 that were used in the clinical trial were characterized by direct whole metagenomic shotgun (MGX) sequencing. The list of genera with spore-forming species identified in any of the three lots is indicated; bracketed genera are pending reassignment in NCBI taxonomy (https://www.ncbi.nlm.nih.gov/taxonomy); unclassified family names within the genera column indicate species without genus assignments. Rows in the table are organized according to the hierarchical taxonomy. The last column indicates the the number of drug lots in which the genera were identified. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f Table S7 . Change in microbiome composition (β-diversity) post-treatment compared to placebo. βdiversity distance (binary jaccard) from baseline for subjects in each treatment group at the given time point, compared placebo. P-value indicates two-sided Mann Whitney-U for the indicated treatment arm compared to placebo. See Table S2 for the number of subjects. J o u r n a l P r e -p r o o f Table S8 . Change in Enterobacteriaceae relative abundance from baseline to 8-weeks posttreatment across arms. The change in Enterobacteriaceae abundance was assessed at 8-weeks post treatment. Only subjects with baseline and 8-week stool samples and subjects with Enterobacteriaceae at baseline (n=29) were included in analyses. Change in Enterobacteriaceae abundance post-treatment was assessed using log 2 fold-change between subjects' baseline and 8-week post-treatment samples. A twosided Wilcoxon signed-rank test was performed to assess if the fold-changes are centered around zero for each arm individually and for Vancomycin/SER-287 weekly and daily treatment arms combined. J o u r n a l P r e -p r o o f Table S9 . Decrease in Enterobacteriaceae abundance is associated with clinical remission. The association Enterobacteriaceae abundance with clinical remission was assessed at 8-weeks post treatment. Only subjects with baseline and 8-week stool samples and subjects with Enterobacteriaceae at baseline (n=29) were included in analyses. Change in Enterobacteriaceae abundance post-treatment was assessed using log 2 fold-change between subjects' baseline and 8-week post-treatment samples. A twosided Wilcoxon signed-rank test was performed to assess if the fold-changes are centered around zero for Vancomycin/SER-287 weekly and daily treatment arms combined in remitters versus non-remitters. J o u r n a l P r e -p r o o f Table S10 . Bile acid and short-chain fatty acid change from baseline to 8 weeks post-treatment. Change in metabolite abundance post-treatment was assessed based on log 2 fold-change between subjects' baseline and post-treatment samples; a Wilcoxon signed-rank test was performed, to assess if the fold-changes are centered around zero. The number of subjects with baseline and post-treatment shortchain fatty acid data is: N=4 for Placebo/Placebo, N=8 for Placebo/SER-287 weekly, N=11 for Vancomycin/SER-287 weekly, N=11 for Vancomycin/SER-287 daily. The number of subjects with baseline and post-treatment bile acid data is: N=3 for Placebo/Placebo, N=8 for Placebo/SER-287 weekly, N=9 for Vancomycin/SER-287 weekly, N=11 for Vancomycin/SER-287 daily.

See file: Table_S10_targeted_metab_tx_stats.xlsx Table S11 . Bile acid and short-chain fatty acid association with clinical remission. Association of metabolite abundance with clinical remission was assessed at 8 weeks post-treatment. A two-sided Mann-Whitney test was performed to assess if the abundance of metabolites significantly differed in remitters compared to non-remitters; subjects in all treatment arms are considered. There are N=29 non-remitters and N=9 remitters with short-chain fatty acid data post-treatment. There are N=27 non-remitters and N=9 remitters with bile acid data post-treatment.

See file: Table_S11_targeted_metab_outcome_stats.xlsx Table S12 . Global metabolomic change from baseline to 8 weeks post-treatment. Change in metabolite abundance post-treatment was assessed based on log 2 fold-change between subjects' baseline and post-treatment samples; a Wilcoxon signed-rank test was performed to assess if the fold-changes were centered around zero. All metabolites are reported with p<0.05 for vancomycin/SER-287 daily dosing and vancomycin/SER-287 weekly dosing arms combined; metabolites with names starting with "X -" indicate compounds of unknown identity; asterisks indicate putative metabolite identities. The number of subjects with baseline and post-treatment data is: N=4 for Placebo/Placebo, N=8 for Placebo/SER-287 weekly, N=11 for Vancomycin/SER-287 weekly, N=11 for Vancomycin/SER-287 daily.

See file: Table_S12_global_metab_tx_stats.xlsx   Table S13 . Global metabolomics association with clinical remission. Association of metabolite abundance with clinical remission was assessed at 8 weeks post-treatment. A two-sided Mann-Whitney test was performed to assess if the abundance of metabolites significantly differed in remitters (N=9) compared to non-remitters (N=29); subjects in all treatment arms are considered. No correction for multiple hypothesis testing was performed. All metabolites are reported with p<0.05; metabolites with names starting with "X -" indicate compounds of unknown identity; asterisks indicate putative metabolite identities.

See file: Table_S13_global_metab_outcome_stats.xlsx J o u r n a l P r e -p r o o f

Diversity of the human intestinal microbial flora

Human gut microbiome viewed across age and geography

Structure, function and diversity of the healthy human microbiome

The microbiome in inflammatory bowel disease: current status and the future ahead

Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches

Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases

Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships

Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease

Dynamics of the human gut microbiome in inflammatory bowel disease

Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment

ACG Clinical Guideline: Ulcerative Colitis in Adults

Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial

Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

Regulatory Considerations for Fecal Microbiota Transplantation Products

Estimating terrestrial biodiversity through extrapolation

Measures of phylogenetic differentiation provide robust and complementary insights into microbial communities

Strains, functions and dynamics in the expanded Human Microbiome Project

Bacteroides-Derived Sphingolipids Are Critical for Maintaining Intestinal Homeostasis and Symbiosis

Gut microbiome structure and metabolic activity in inflammatory bowel disease

Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis

Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis

Ulcerative Colitis: Clinical Trial Endpoints Guidance for Industry

The ecology of secondary succession

To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes

The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing

Clostridium difficile and the microbiota

SER-109, an Investigational Microbiome Drug to Reduce Recurrence after Clostridioides difficile infection: Lessons Learned from a Phase 2 Trial

Commensal Clostridia: leading players in the maintenance of gut homeostasis

Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis

The ecology of the microbiome: Networks, competition, and stability

Microbiome: Should we diversify from diversity?

Bacterial-induced hepoxilin A3 secretion as a pro-inflammatory mediator

Distinct isoforms of phospholipase A2 mediate the ability of Salmonella enterica serotype typhimurium and Shigella flexneri to induce the transepithelial migration of neutrophils

Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms

Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms

The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Fecal Microbiota Transplantation for Dysbiosis -Predictable Risks

Curbing our enthusiasm for fecal transplantation in ulcerative colitis

Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic

Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin

The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis

Trimmomatic: a flexible trimmer for illumina sequence data

Fast gapped-read alignment with Bowtie 2

Microbial co-occurrence relationships in the human microbiome

MetaPhIAn2 for enhanced metagenomic taxonomic profiling

To be eligible for enrollment, a subject was required meet all of the following criteria before undergoing any study-related procedures:1.Signed informed consent.

Male or female, ≥ 18 years of age.

Ulcerative colitis diagnosed by routine clinical, radiographic, endoscopic and pathologic criteria.

Active mild-to-moderate UC as determined by lower endoscopy (flexible sigmoidoscopy or colonoscopy) within approximately 3 days of randomization to study, defined as: a.Total Modified Mayo score of 4 to 10, inclusive b.Modified Mayo endoscopic subscore of ≥ 1, with evidence of mucosal lesions c.At least 15 cm of disease from anal verge.

If female, subject is non-lactating, and either: a. Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy b.Of childbearing potential and is practicing at least 1 highly effective method of birth control including the barrier method; oral or parenteral contraceptives; a vasectomized partner; or abstinence from sexual intercourse. The investigator will discuss with the subject the option of practicing more than 1 of the above methods for the duration of the study. 6.If male and partner is of childbearing potential, subject agrees to practice at least one highly effective method of birth control for the duration of the study. Any of the following was regarded as a criterion for exclusion from the trial:1. Fever > 38.3°C.

Known or suspected toxic megacolon and/or known small bowel ileus.

Known history of Crohn's disease.

Subjects with serum albumin ≤ 2.5 g/dL at baseline.

CMV polymerase chain reaction (PCR) positive from blood plasma at screening. 6.Known stool tests positive for ova and/or parasites, or positive stool culture, within the 30 days prior to enrollment. 7.Subjects on cyclosporine or triple immunosuppression. Triple immunosuppression will include any three of the following classes of drugs taken in combination: steroids (i.e., prednisone, budesonide, budesonide MMX®), immunosuppressant (i.e., methotrexate, azathioprine, 6-mercaptopurine), and/or other immunosuppressant (i.e., tacrolimus, mycophenolate mofetil [CellCept]). 8.Biologic medication (infliximab, adalimumab, golimumab, certolizumab, vedolizumab, ustekinumab, or natalizumab) use within 3 months prior to screening. 9.Known active malignancy, except for basal cell skin cancer or squamous cell skin cancer. 10.Subjects with previous colectomy, ostomy, J-pouch, or previous intestinal surgery (excluding cholecystectomy, appendectomy).

Subjects with known history of celiac disease or gluten enteropathy. 12.Subjects with Clostridium difficile positive stool toxin test performed by the Central lab at Screening Visit. 13.Antibiotic use within 1 month prior to randomization.